GSK Investigational Site
Leuven, 3000, Belgium
NCT Number: NCT01706185
This study aims to analyze the incidence of expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME tumor antigens in cancer tissue from patients with pathologically demonstrated bladder cancer.
Looking for future studies?
Notify MeAll sexes
Observational
Leuven, 3000, Belgium
There will be no procedure(s) or treatment(s) carried out on patients. All data and samples will be taken from those already stored at the investigation sites. Clinical data collected will include patient demographics (age, gender), Tumor, Node, Metastasis (staging system) [TNM stage], and histopathologic description only. Strict anonymity of patient data will be maintained.
This retrospective study is based upon the analysis of archived formalin-fixed paraffin-embedded tissue samples and patient-related data already available at the investigational site.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For inclusion of a tissue sample, all of the following criteria must be met:
There are no restrictions regarding operative technique (cystectomy or cystoscopy).
Exclusion criteria
Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
Time frame: Up to 1 year
GlaxoSmithKline
Industry
Analysis of the Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01352962
Adnexal Diseases, Bronchial Neoplasms
Bethesda, Maryland, United States
View Trial DetailsNCT03924856
Bladder Cancer, Female Urogenital Diseases
La Jolla, California, United States
View Trial DetailsNCT04081246
Bladder Cancer, Bladder Neoplasm
Hong Kong
View Trial DetailsNCT05512377
Biliary Tract Cancer, Biliary Tract Diseases
Mobile, Alabama, United States
View Trial Details